Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
About this item
Full title
Author / Creator
Bergmark, Brian A. , Marston, Nicholas A. , Prohaska, Thomas A. , Alexander, Veronica J. , Zimerman, André , Moura, Filipe A. , Murphy, Sabina A. , Goodrich, Erica L. , Zhang, Shuanglu , Gaudet, Daniel , Karwatowska-Prokopczuk, Ewa , Tsimikas, Sotirios , Giugliano, Robert P. , Sabatine, Marc S. and Bridge–TIMI 73a Investigators
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In a phase 2b trial involving patients with hypertriglyceridemia, the use of olezarsen (which targets
APOC3
mRNA) for 6 months reduced triglyceride levels by approximately 50% as compared with placebo.
Alternative Titles
Full title
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_3034776481
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_3034776481
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2402309
